The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview

Ejemplares similares

• Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
  por: Tamás Ágh, et al.
  Publicado: (2025)
• Medication adherence during the run‐in phase of clinical trials: A systematic review of methodological and reporting rigour
  por: Non Davies, et al.
  Publicado: (2025)
• A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice
  por: Lauren Fraser, et al.
  Publicado: (2025)
• Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience
  por: Juliette A. van den Noort, et al.
  Publicado: (2025)
• Randomization in phase II trials: No exemption based on sample size
  por: Theodor Framke, et al.
  Publicado: (2025)